Affimed will team up with Roche to conduct a Phase 1/2a clinical trial investigating its innate cell engager AFM24 — a form of immunotherapy — in combination with Tecentriq (atezolizumab) for the treatment of EGFR-positive solid cancers that progressed despite prior therapies. Under a new collaboration agreement, Affimed will fund and conduct the trial, while Roche will be supplying its immune checkpoint inhibitor Tecentriq. “This collaboration with Roche is an important step in our continued…

You must be logged in to read/download the full post.